

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

FASENRA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Blood eosinophil count of greater than or equal to 150 cells/mcL within the past 3 months.

Age Restrictions:

12 years of age or older.

Prescriber Restrictions:

Prescribed by or in consultation with an allergist, pulmonologist, or immunologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed in combination with ONE inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced AND Prescribed in combination with ONE long-acting beta-agonist (e.g., salmeterol, formoterol, vilanterol), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

FERRIPROX

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of deferoxamine, Exjade or Jadenu, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

FIORINAL WITH CODEINE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of naproxen and ibuprofen, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

FIRAZYR

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Member is not using Firazyr in combination with another FDA-approved product for treatment of acute HAE attacks (e.g., Berinert, Ruconest, Kalbitor).

Age Restrictions:

Age 18 or greater.

Prescriber Restrictions:

Prescribed by or in consultation with an immunologist, allergist, or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

FIRDAPSE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Confirmation of a baseline clinical muscle strength assessment (examples may include but are not limited to the Quantitative Myasthenia Gravis (QMG) score, triple-timed up-and-go test (3TUG), Timed 25-foot Walk test (T25FW)). CONTINUATION OF THERAPY: Member is responding positively to therapy as evidenced by clinical muscle strength assessments.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

FLECTOR

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Cancer pain.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

Acute Pain: 4 weeks. Cancer pain: Through the end of the Plan contract year.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

FLUOROURACIL

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

FORTEO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Total duration of therapy on parathyroid hormone (PTH) analogs (e.g., Tymlos, Forteo) has not exceeded 2 years.

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of a bisphosphonate (e.g., alendronate) unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

GALAFOLD

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Amenable GLA variants (mutations) associated with benign phenotypes (i.e., phenotypes known not to cause Fabry disease), including the following GLA mutation: c.937G to T, (p.(D313Y)).

Required Medical Information:

Presence of at least one amenable GLA variant (mutation) as confirmed by one of the following resources: Galafold Prescribing Information brochure (package insert - Section 12, Table 2), Amicus Fabry GLA Gene Variant Search Tool: <http://www.fabrygenevariantsearch.com/hcp>, or Amicus Medical Information at 1-877-4AMICUS or medinfousa@amicusrx.com.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a clinical geneticist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

GANCICLOVIR

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

GATTEX

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Member has been dependent on parenteral nutrition or other intravenous support for at least 12 months.
CONTINUATION OF THERAPY: Requirement for parenteral nutrition or other intravenous support has decreased since initiation of Gattex therapy.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a gastroenterologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

GILENYA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Baseline QTc interval greater than or equal to 500 msec.

Required Medical Information:

Age Restrictions:

10 years of age or older.

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

GILOTRIF

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

NON-SMALL CELL LUNG CANCER: Member meets one of the following (a or b): a) disease is positive for a sensitizing EGFR mutation (e.g., exon 19 deletion or insertion, exon 21 point mutation (L858R, L861Q), exon 18 point mutation (G719X), exon 20 point mutation (S768I)), OR b) disease is squamous cell carcinoma histology with progression after platinum-based chemotherapy (e.g., cisplatin, carboplatin).

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

GLATIRAMER

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

GLIMEPIRIDE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced:
glipizide or glipizide/metformin combination product.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

GLYBURIDE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced:
glipizide or glipizide/metformin combination product.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

GLYBURIDE/METFORMIN

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced:
glipizide or glipizide/metformin combination product.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

HYDROXYZINE PAMOATE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Pruritus: Failure of one of the following topical agents, unless contraindicated or clinically significant adverse effects are experienced: betamethasone, hydrocortisone, triamcinolone, fluticasone, clobetasol, fluocinonide or fluocinolone. Anxiety: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: venlafaxine, buspirone, duloxetine or escitalopram. All other FDA approved indications: Patient is continuing on this medication without adverse effects.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ICLUSIG

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): disease is Philadelphia chromosome positive (Ph+).

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

IDH1FA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Presence of an isocitrate dehydrogenase-2 (IDH2) mutation.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

For age less than 60 years, disease has relapsed or is refractory following treatment with a first line chemotherapy regimen (e.g., cytarabine, idarubicin, daunorubicin, Vyxeos, cladribine, Rydapt, Mylotarg).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ILARIS

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Acute gouty arthritis.

Exclusion Criteria:

Required Medical Information:

Confirmation of current weight.

Age Restrictions:

Cryopyrin-Associated Periodic Syndromes: 4 years and older. All other covered indications: 2 years and older.

Prescriber Restrictions:

SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: Prescribed by or in consultation with a dermatologist, rheumatologist, or gastroenterologist. ALL OTHER COVERED INDICATIONS: Prescribed by or in consultation with a rheumatologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ILUMYA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a rheumatologist or dermatologist.

Coverage Duration:

12 months.

Other Criteria:

Failure of one of the following unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin. Failure of one of the following unless contraindicated or clinically significant adverse effects are experienced: Cosentyx, Humira, Inflectra, Remicade, Stelara, Taltz, and Tremfya.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

IMATINIB

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

CHRONIC MYELOID LEUKEMIA (CML), ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): disease is Philadelphia chromosome positive. CHRONIC MYELOMONOCYTIC LEUKEMIA: disease is positive for a platelet-derived growth factor receptor (PDGFR) mutation or a 5q3133 mutation.

MYELOYDYSPLASTIC/MYELOPROLIFERATIVE DISEASES: disease is positive for a PDGFR mutation.

AGGRESSIVE SYSTEMIC MASTOCYTOSIS: disease is D816V c-Kit mutation negative or c-Kit mutational status is unknown. MELANOMA: disease is KIT-positive.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

IMBRUVICA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

CHRONIC GRAFT-VERSUS-HOST DISEASE: Prescribed by or in consultation with an oncologist, hematologist, or bone marrow transplant specialist. ALL OTHER INDICATIONS: Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

IMIPRAMINE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Depression: Failure of one of the following generic antidepressants, unless contraindicated or clinically significant adverse effects are experienced: bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine succinate, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine or venlafaxine XR.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

INDOMETHACIN

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of naproxen and sulindac, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

INFLECTRA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Psoriatic Arthritis/Plaque Psoriasis: Prescribed by or in consultation with a rheumatologist or dermatologist.
Crohn's Disease/Ulcerative Colitis: Prescribed by or in consultation with a gastroenterologist. Rheumatoid Arthritis/Ankylosing Spondylitis: Prescribed by or in consultation with a rheumatologist.

Coverage Duration:

12 months.

Other Criteria:

Rheumatoid Arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.
Plaque Psoriasis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

INGREZZA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Development of tardive dyskinesia is secondary to a centrally acting dopamine receptor blocking agent (neuroleptic) (e.g., first- or second-generation antipsychotics such as chlorpromazine or aripiprazole, antiemetics such as promethazine or metoclopramide, the tri-cyclic antidepressant amoxapine).

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a psychiatrist or neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

INLYTA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

RENAL CELL CARCINOMA WITH CLEAR CELL HISTOLOGY: Failure of one prior therapy (e.g., Votrient, Sutent), unless contraindicated or clinically significant adverse effects are experienced. DIFFERENTIATED THYROID CARCINOMA: Failure of Lenvima or Nexavar unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

INTERFERON BETA-1A

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

INTERFERON BETA-1B

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

INTUNIV

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Attention Deficit Hyperactivity Disorder: Failure of both of the following, unless contraindicated or clinically significant adverse effects are experienced: amphetamine-based stimulant and methylphenidate based-stimulant.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

JAKAFI

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

POLYCYTHEMIA VERA: Failure of hydroxyurea, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

JUXTAPID

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of Repatha 420 mg, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

JYNARQUE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a nephrologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

KADCYLA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Kadcyla will be used as a single-agent therapy.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

KALYDECO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Presence of one mutation in the CFTR gene that is responsive to ivacaftor. Confirmation that a homozygous F508del mutation in the CFTR gene is not present.

Age Restrictions:

6 months of age or older.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

KETOROLAC TROMETHAMINE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Patients with active peptic ulcer disease. Advanced renal impairment or at risk for renal failure due to volume depletion. Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk for bleeding. Patient currently receiving aspirin or NSAIDs (non-steroidal anti-inflammatory drugs). Patient currently receiving probenecid or pentoxifylline.

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

5 days.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

KEVZARA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a rheumatologist.

Coverage Duration:

12 months.

Other Criteria:

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

KISQALI(Kisqali , Kisqali Femara Co-Pack)

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Breast cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and advanced or metastatic.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

For Kisqali: Prescribed in combination with an aromatase inhibitor (e.g., letrozole, anastrozole, or exemestane), fulvestrant, or tamoxifen. If prescribed in combination with tamoxifen: Medical justification supports need to use tamoxifen over an aromatase inhibitor or fulvestrant. For men receiving an aromatase inhibitor: Prescribed in combination with an agent that suppresses testicular steroidogenesis (e.g., gonadotropin-releasing hormone agonists).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

KORLYM

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an endocrinologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

KUVAN

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Recent (within 90 days) phenylalanine (Phe) blood level is greater than 360 micromol/L. CONTINUATION OF THERAPY: Confirmation of a reduction in Phe blood levels since initiation of therapy.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a metabolic or genetic disease specialist.

Coverage Duration:

Initial: 3 months. Reauthorization: 12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

KYNAMRO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of Repatha 420 mg, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LATUDA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of two of the following atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LAZANDA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Age 18 or greater

Prescriber Restrictions:

Coverage Duration:

Through the end of the Plan contract year.

Other Criteria:

Patient is already taking and is tolerant to around-the-clock opioid therapy. Patients are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LEMTRADA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Failure of TWO of the following, unless contraindicated or clinically significant adverse effects are experienced: Aubagio, Tecfidera, Gilenya, Avonex, Betaseron, Plegridy, glatiramer, Copaxone, Glatopa, Extavia or Rebif.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LENVIMA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

RENAL CELL CARCINOMA: Prescribed in combination with Afinitor AND if histology is clear cell or unknown, failure of a regimen consisting of or including one of the following drugs unless contraindicated or clinically significant adverse effects are experienced: Avastin, Cabometyx, Inlyta, Nexavar, Opdivo, Proleukin, Sutent, Tarceva, Torisel, Votrient, or Yervoy. MEDULLARY THYROID CARCINOMA: Failure of Cometriq or Caprelsa unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LEUKINE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

AML following induction therapy, Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation, Following autologous peripheral blood progenitor cell or bone marrow transplantation (BMT) in members with NHL, ALL, HL for acceleration of myeloid reconstitution, Following allogeneic BMT for acceleration of myeloid reconstitution, Acute Radiation Syndrome: Failure of Neupogen, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LIDODERM

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Diabetic peripheral neuropathy. Cancer-related neuropathic pain.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LONSURF

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

COLORECTAL CANCER: Confirmation that the patient does or does not have the RAS (KRAS or NRAS) wild type gene. GASTRIC CANCER, GASTROESOPHAGEAL ADENOCARCINOMA: Confirmation that the patient does or does not have a HER2/neu-positive tumor.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

COLORECTAL CANCER: If tumor expresses the RAS wild type gene, failure of Erbitux or Vectibix, unless contraindicated or clinically significant adverse effects are experienced. GASTRIC CANCER, GASTROESOPHAGEAL ADENOCARCINOMA: If tumor is HER2/neu-positive (i.e., HER2-overexpressing), failure of Herceptin, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LORBRENA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

NON-SMALL CELL LUNG CANCER: Disease is ALK or ROS1 positive.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

For ALK-positive disease: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Alecensa, Alunbrig, Zykadia. For ROS1-positive disease: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Xalkori, Zykadia.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LOTROXEX

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Male patients.

Required Medical Information:

Female patient with irritable bowel symptoms persisting for at least 6 months.

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LUCEMYRA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Diagnosis of opioid dependence (may be limited to physiologic dependence/tolerance) or opioid use disorder. Member is currently or will be undergoing abrupt opioid discontinuation within the next seven days and one of the following: member has taken one or more opioids for at least the last three weeks OR an opioid antagonist (e.g., naltrexone) has been or will be administered after a period of opioid use. Medical justification supports why an opioid taper (e.g., with buprenorphine, methadone or other opioid) cannot be used. Lucemyra has not been prescribed for a prior opioid withdrawal event within the last 30 days or medical justification supports retreatment.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a physician specializing in one of the following areas: emergency medicine/inpatient care, pain management, addiction psychiatry.

Coverage Duration:

14 days per course of treatment.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

LYNPARZA TABLET

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Ovarian, fallopian tube or primary peritoneal cancer: Mutations in the BRCA genes OR member has a complete or partial response to two or more platinum-based chemotherapy regimens. Breast Cancer: Mutations in the BRCA genes and confirmation of human epidermal growth factor receptor 2 (HER2)-negative disease.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

MAVYRET

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Treatment-experienced patients with both NS3/4A protease inhibitor and NS5A inhibitor.

Required Medical Information:

If cirrhosis is present, confirmation of Child-Pugh A status. Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSAs available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

Coverage Duration:

8 to 16 weeks based on genotype, cirrhosis status, prior treatment regimen.

Other Criteria:

If member has been previously treated with an HCV regimen containing NS5A inhibitor or an NS3/4A protease inhibitor, but not both, member has genotype 1.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

MEGACE

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

BREAST CANCER AND ENDOMETRIAL CANCER: Megestrol acetate is being used for palliative treatment.

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

ANOREXIA AND CACHEXIA ASSOCIATED WITH AIDS: Failure of dronabinol and oxandrolone, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

MEGACE ES

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

BREAST CANCER AND ENDOMETRIAL CANCER: Megestrol acetate is being used for palliative treatment.

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

ANOREXIA AND CACHEXIA ASSOCIATED WITH AIDS: Failure of dronabinol and oxandrolone, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

MEKINIST

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

MELANOMA: Positive for BRAF V600E or V600K mutation. NON-SMALL CELL LUNG CANCER, ANAPLASTIC THYROID CANCER: Positive for BRAF V600E mutation.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

NON-SMALL CELL LUNG CANCER, ANAPLASTIC THYROID CANCER: Prescribed in combination with Tafinlar.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

MEKTOVI

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Positive for BRAF V600E or V600K mutation.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed in combination with Braftovi.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

METAXALONE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

METHAMPHETAMINE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Treatment of obesity.

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

METHOCARBAMOL

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

METHOTREXATE INJ

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, RHEUMATOID ARTHRITIS: Prescribed by or in consultation with a rheumatologist. PSORIASIS: Prescribed by or in consultation with a rheumatologist or a dermatologist.

Coverage Duration:

12 months.

Other Criteria:

Failure of generic methotrexate injection, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

MIRVASO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Erythema of rosacea with papules or pustules: Failure of topical metronidazole, oral doxycycline or Finacea, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

MOZOBIL

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Member is scheduled to receive autologous stem cell transplantation.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed in combination with a granulocyte-colony stimulating factor (G-CSF) (i.e., Neupogen, Zarxio, Granix, or Nivestym).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

MULPLETA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Recent (within the past 14 days) platelet count is less than $50 \times 10^9/L$. Member is scheduled to undergo a medical or dental procedure within the next 30 days.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a hematologist, hepatologist, or gastroenterologist.

Coverage Duration:

4 weeks.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NAMENDA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Vascular dementia.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 59 years and younger. Prior authorization is not required for patients 60 years and older.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NATPARA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Recent (dated within the last 30 days) serum calcium level is less than 7.5 mg/dL. Recent (dated within the last 30 days) lab result shows sufficient 25-hydroxyvitamin D stores (at least 50 nmol/L or 20 ng/mL). CONTINUATION OF THERAPY: Maintained on therapy with positive response as evidenced by a recent (dated within the last 90 days) serum calcium level within 8-9 mg/dL.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an endocrinologist.

Coverage Duration:

12 months.

Other Criteria:

Failure of an active form of vitamin D (e.g., calcitriol) unless contraindicated or clinically significant adverse events are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NERLYNX

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed in combination with capecitabine for recurrent brain metastases OR Confirmation of previous treatment with trastuzumab as adjuvant therapy and disease is hormone receptor positive or early stage (stage 1-3).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NEULASTA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Mobilization of peripheral-blood progenitor cells prior to autologous transplantation. Supportive care post autologous hematopoietic cell transplantation.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NEUPOGEN

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Myelodysplastic syndrome. Neutropenia in patients with HIV/AIDS.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NINLARO

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed in combination with dexamethasone.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NORTHERA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NUBEQA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Concurrent use of a gonadotropin-releasing hormone (GnRH) analog (e.g., Zoladex, Vantas, leuprolide/Lupron Depot, Eligard, Trelstar, Firmagon) or past bilateral orchiectomy. Disease is not metastatic.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or urologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NUCALA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Blood eosinophil count of greater than or equal to 150 cells/mcL within the past 3 months.

Age Restrictions:

ASTHMA: 12 years of age or older.

Prescriber Restrictions:

ASTHMA: Prescribed by or in consultation with an allergist, pulmonologist, or immunologist. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: Prescribed by or in consultation with a pulmonologist, immunologist, rheumatologist, or nephrologist.

Coverage Duration:

12 months.

Other Criteria:

ASTHMA: Prescribed in combination with ONE inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced AND Prescribed in combination with ONE long-acting beta-agonist (e.g., salmeterol, formoterol, vilanterol), unless contraindicated or clinically significant adverse effects are experienced. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: Failure of ONE glucocorticoid, unless contraindicated or clinically significant adverse events are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NUEDEXTA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NUPLAZID

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

NUZYRA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Request is for continuation of therapy initiated in an acute care hospital from which member was discharged OR Culture and sensitivity (C&S) report for the current infection shows isolated pathogen is an organism susceptible to omadacycline, unless provider confirms that obtaining a C&S report is not feasible.

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

14 days.

Other Criteria:

For members initiating Nuzyra therapy outside of an acute care hospital, one of the following (a, b, or c): a) If a C&S report is available: Failure of 2 antibiotics to which the isolated pathogen is susceptible (if available) per C&S report, unless all are contraindicated or clinically significant adverse effects are experienced. b) C&S report shows resistance or lack of susceptibility of the isolated pathogen to all antibiotics FDA-approved for member's diagnosis. c) If provider confirms that obtaining a C&S report is not feasible: Failure of 2 antibiotics indicated for member's diagnosis (if available), unless all are contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

OCALIVA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a hepatologist or gastroenterologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed in combination with ursodeoxycholic acid unless contraindicated or clinically significant adverse effects are experienced to ursodeoxycholic acid.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

OCREVUS

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Relapsing Forms Of Multiple Sclerosis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Aubagio, Tecfidera, Gilenya, Avonex, Betaseron, Plegridy, glatiramer, Copaxone, Glatopa, Extavia or Rebif.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ODOMZO

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

OFEV

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

OLUMIANT

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a rheumatologist.

Coverage Duration:

12 months.

Other Criteria:

Failure of one of the following agents, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine, or auranofin. Failure of at least one TNF inhibitor unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

OPSUMIT

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ORENITRAM

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ORLISSA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

For 200 mg twice daily requests, members with osteoporosis.

Required Medical Information:

Continuation of therapy: improvement in dysmenorrhea, dyspareunia, pelvic pain/induration/tenderness, or size of endometrial lesions. Total duration of therapy has not exceeded 6 months for 200 mg twice daily or 24 months for 150 mg once daily dosing.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a gynecologist.

Coverage Duration:

200 mg twice daily: 6 months. 150 mg once daily: 12 months.

Other Criteria:

Failure of ONE non-steroidal anti-inflammatory drug (e.g., ibuprofen, naproxen, fenoprofen, ketoprofen, mefenamic acid, meclofenamate, indomethacin, tolmetin, diclofenac, etodolac, diflunisal, meloxicam, piroxicam) or ONE progestin-containing agent (e.g., norethindrone, ethinyl estradiol with (desogestrel, ethynodiol diacetate, drospirenone, etonogestrel, levonorgestrel, norelgestromin, norethindrone, norgestimate, or norgestrel), estradiol valerate/dienogest, mestranol/norethindrone, depot injectable medroxyprogesterone acetate), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ORKAMBI

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Presence of homozygous F508del mutation in an FDA-cleared cystic fibrosis mutation test.

Age Restrictions:

2 years of age or older.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

OXERVATE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an ophthalmologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PALYNZIQ

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Recent (within 90 days) phenylalanine (Phe) blood level is greater than 600 micromol/L. CONTINUATION OF THERAPY: Positive response as evidenced by one of the following (a, b, or c): a) Blood Phe level has decreased by at least 20% from pre-treatment baseline, b) Blood Phe level is less than or equal to 600 micromol/L, c) Member has been using 20 mg per day for at least 6 months, but a dose titration to 40 mg per day is being requested after failure to meet therapeutic targets (a or b above).

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an endocrinologist, metabolic disease specialist, or genetic disease specialist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PENNSAID

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of ONE oral non-steroidal anti-inflammatory drug (e.g., ibuprofen, naproxen, fenoprofen, ketoprofen, mefenamic acid, meclofenamate, indomethacin, tolmetin, diclofenac, etodolac, diflunisal, meloxicam, piroxicam), unless all are contraindicated or clinically significant adverse effects are experienced. Failure of either diclofenac 1.5% topical solution or diclofenac 1% topical gel, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PERSERIS

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of TWO of the following atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: aripiprazole, ziprasidone, quetiapine, olanzapine, risperidone, asenapine, iloperidone, paliperidone.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PHENOBARBITAL

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Partial seizures: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: carbamazepine, phenytoin, topiramate, tiagabine, levetiracetam, gabapentin, lamotrigine, oxcarbazepine, primidone or divalproex. Generalized seizures: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: carbamazepine, phenytoin, topiramate, levetiracetam, primidone or lamotrigine.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PIQRAY

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Hormone receptor (HR)-positive (i.e., estrogen or progesterone receptor [ER/PR]-positive), HER2-negative, advanced (locally recurrent) or metastatic, and positive for PIK3CA-mutation.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed in combination with fulvestrant after disease progression on an endocrine therapy (e.g., anastrozole, exemestane, fulvestrant, toremifene, letrozole, tamoxifen, or megestrol acetate).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PRALUENT

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Heterozygous Familial Hypercholesterolemia : Confirmation (e.g., medical records, chart notes, laboratory values) of LDL level suggestive of a diagnosis of heterozygous familial hypercholesterolemia (e.g., Adults: LDL greater than 190 mg/dL). Hypercholesterolemia: Confirmation of an LDL of 70 mg/dL or greater AND history of clinical atherosclerotic cardiovascular disease defined as one of the following: Acute coronary syndromes, Myocardial Infarction, Stable or unstable angina, Coronary or other arterial revascularization (e.g., percutaneous coronary intervention or coronary artery bypass graft surgery), Stroke, Peripheral artery disease presumed to be of atherosclerotic origin, Transient ischemic attack (TIA), Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging), Carotid artery occlusion greater than 50% without symptoms, Renal artery stenosis or renal artery stent procedure. CONTINUATION OF THERAPY: Confirmation of LDL reduction while on Praluent therapy AND, if tolerated, confirmation of continued statin therapy at the maximally tolerated dose.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist.

Coverage Duration:

6 months.

Other Criteria:

Failure of two of the following at maximally tolerated doses, unless contraindicated or clinically significant adverse effects are experienced: atorvastatin, rosuvastatin, simvastatin, ezetimibe/simvastatin, pitavastatin, pravastatin, fluvastatin, or lovastatin.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PREVYMIS

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Member is receiving pimozide or ergot alkaloids. Member is receiving cyclosporine co-administered with pitavastatin or simvastatin.

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncology, hematology, infectious disease, or transplant specialist.

Coverage Duration:

Through day 100 post-transplantation.

Other Criteria:

Failure of generic valacyclovir or generic ganciclovir, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PROLASTIN C

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a pulmonologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PROLIA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Hypocalcemia (unless corrected prior to initiating therapy).

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

For men with non-metastatic prostate cancer: Receiving or has received androgen deprivation therapy [i.e., leuprolide (Lupron), bicalutamide (Casodex) or Nilandron]. For women with breast cancer: Receiving or has received adjuvant aromatase inhibitor therapy [i.e., anastrozole (Arimidex), exemestane (Aromasin) or letrozole (Femara)].

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PROMACTA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Thrombocytopenia in Chronic Hepatitis C: Confirmation of current or planned interferon-based treatment of chronic hepatitis C.

Age Restrictions:

Prescriber Restrictions:

CHRONIC IMMUNE THROMBOCYTOPENIA, SEVERE APLASTIC ANEMIA: Prescribed by or in consultation with a hematologist. THROMBOCYTOPENIA IN CHRONIC HEPATITIS C: Prescribed by or in consultation with a hematologist, gastroenterologist, or an infectious disease specialist.

Coverage Duration:

12 months.

Other Criteria:

Chronic Immune (Idiopathic) Thrombocytopenia: Failure of a corticosteroid (e.g., prednisone, methylprednisolone, or dexamethasone), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PROTOPIC

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Tacrolimus 0.1%: 16 years and older.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of two medium to high potency topical corticosteroids (e.g., amcinonide, fluticasone propionate, triamcinolone acetonide, betamethasone valerate, fluocinolone acetonide, hydrocortisone butyrate, mometasone furoate, desoximetasone, fluocinonide or betamethasone dipropionate), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PROVIGIL

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Multiple sclerosis-related fatigue.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

PURIXAN

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

One of the following: Failure of mercaptopurine tablets, unless contraindicated or clinically significant adverse effects are experienced OR member has a swallowing disorder or an inability to swallow tablets or capsules..

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

QUALAQUIN

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Babesiosis. Plasmodium vivax malaria.

Exclusion Criteria:

For the treatment or prevention of nocturnal leg cramps.

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

Malaria: 7 days. Babesiosis: 7-10 days.

Other Criteria:

Plasmodium vivax malaria: Infection is chloroquine-resistant.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

RADICAVA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Forced vital capacity greater than or equal to 80%, disease duration of less than or equal to 2 years, functionally retains most activities of daily living (defined as a baseline revised ALS Functional Rating Scale (ALSFRS-R) score with greater than or equal to 2 points in each of the 12 items, meets diagnostic criteria of definite or probable amyotrophic lateral sclerosis (ALS) based on El Escorial revised criteria. CONTINUATION OF THERAPY: Member continues to retain most activities of daily living, forced vital capacity greater than or equal to 80%, and ALSFRS-R score with greater than or equal to 2 points in each of the 12 items.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

6 months.

Other Criteria:

Prescribed in combination with riluzole unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

RAYALDEE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Patient has stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D level less than 30 ng/mL.

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

REMICADE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Wegener's Granulomatosis.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Psoriatic Arthritis/Plaque Psoriasis: Prescribed by or in consultation with a rheumatologist or dermatologist.
Crohn's Disease/Ulcerative Colitis: Prescribed by or in consultation with a gastroenterologist. Rheumatoid Arthritis/Ankylosing Spondylitis: Prescribed by or in consultation with a rheumatologist.

Coverage Duration:

12 months.

Other Criteria:

Rheumatoid Arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.
Plaque Psoriasis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

REPATHA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Heterozygous or Homozygous Familial Hypercholesterolemia : Confirmation (e.g., medical records, chart notes, laboratory values) of LDL level suggestive of a diagnosis of familial hypercholesterolemia (e.g., Adults: LDL greater than 190 mg/dL). Hypercholesterolemia: Confirmation of an LDL of 70 mg/dL or greater AND history of clinical atherosclerotic cardiovascular disease defined as one of the following: Acute coronary syndromes, Myocardial Infarction, Stable or unstable angina, Coronary or other arterial revascularization (e.g., percutaneous coronary intervention or coronary artery bypass graft surgery), Stroke, Peripheral artery disease presumed to be of atherosclerotic origin, Transient ischemic attack (TIA), Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging), Carotid artery occlusion greater than 50% without symptoms, Renal artery stenosis or renal artery stent procedure. CONTINUATION OF THERAPY: Confirmation of LDL reduction while on Repatha therapy AND, if tolerated, confirmation of continued statin therapy at the maximally tolerated dose.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist.

Coverage Duration:

6 months.

Other Criteria:

Failure of two of the following at maximally tolerated doses, unless contraindicated or clinically significant adverse effects are experienced: atorvastatin, rosuvastatin, simvastatin, ezetimibe/simvastatin, pitavastatin, pravastatin, fluvastatin, or lovastatin.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

REVATIO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Members on concomitant nitrates (e.g., Nitrodur, Nitrobid, Nitrostat, Isordil, Ismo). Members on concomitant guanylate cyclase stimulator, such as riociguat (Adempas).

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

REVC0VI

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an immunologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

REVLIMID

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

REXULTI

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of aripiprazole and one of the following generic atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: risperidone, olanzapine, quetiapine, ziprasidone.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

RUBRACA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Mutations in the BRCA genes OR member has a complete or partial response to two or more platinum-based chemotherapy regimens.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

RYDAPT

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Acute Myeloid Leukemia: Positive for the FLT3 mutation.

Age Restrictions:

Prescriber Restrictions:

Acute Myeloid Leukemia: Prescribed by or in consultation with an oncologist or hematologist. Advanced Systemic Mastocytosis: Prescribed by or in consultation with an oncologist, allergist, or immunologist.

Coverage Duration:

12 months.

Other Criteria:

Acute Myeloid Leukemia: for induction therapy, prescribed in combination with cytarabine and daunorubicin OR for consolidation therapy, prescribed in combination with cytarabine.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SILIQ

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a rheumatologist or dermatologist.

Coverage Duration:

12 months.

Other Criteria:

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced:
methotrexate, cyclosporine or acitretin.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SIMPONI(auto-injector, prefilled syringe)

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

PSORIATIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist or dermatologist. ULCERATIVE COLITIS: Prescribed by or in consultation with a gastroenterologist. RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: Prescribed by or in consultation with a rheumatologist.

Coverage Duration:

12 months.

Other Criteria:

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SIMPONI ARIA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

PSORIATIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist or dermatologist.
RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: Prescribed by or in consultation with a rheumatologist.

Coverage Duration:

12 months.

Other Criteria:

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SOMA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SOMAVERT

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an endocrinologist.

Coverage Duration:

12 months.

Other Criteria:

Inadequate response to surgery or radiation therapy, unless surgery or radiation therapy is not appropriate for the patient.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SOVALDI

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Criteria will be applied consistent with current AASLD-IDSA guidance.

Exclusion Criteria:

Required Medical Information:

Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSA available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

Coverage Duration:

Criteria will be applied consistent with current AASLD-IDSA guidance.

Other Criteria:

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: Mavyret, Harvoni, Epclusa, Vosevi, and Zepatier for applicable genotypes.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SPRAVATO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Currently on an oral antidepressant (must not be an agent previously tried and failed). CONTINUATION OF THERAPY: Member is responding positively to therapy and is using Spravato in combination with an oral antidepressant.

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

Initial: 4 weeks. Reauthorization: 6 months.

Other Criteria:

Failure of two antidepressants (e.g., selective serotonin reuptake inhibitor [SSRI], serotonin-norepinephrine reuptake inhibitor [SNRI], tricyclic antidepressant [TCA], bupropion, mirtazapine) from two different classes, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SPRITAM

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Medical justification must be provided why patient cannot take generic levetiracetam tablets or liquid.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SPRYCEL

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Confirmation that the member has Philadelphia chromosome positive disease.

Age Restrictions:

Prescriber Restrictions:

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Prescribed by or in consultation with an oncologist or hematologist. ALL OTHER COVERED ONCOLOGY INDICATIONS: Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

GASTROINTESTINAL STROMAL TUMOR: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: imatinib, Sutent or Stivarga.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

STELARA IV

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a gastroenterologist.

Coverage Duration:

4 weeks.

Other Criteria:

CROHN'S DISEASE: Failure of Humira or Remicade and one of the following, unless contraindicated or clinically significant adverse effects are experienced: 6-mercaptopurine, azathioprine or methotrexate.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

STELARA SC

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

PSORIATIC ARTHRITIS, PLAQUE PSORIASIS: Prescribed by or in consultation with a rheumatologist or dermatologist. CROHN'S DISEASE: Prescribed by or in consultation with a gastroenterologist.

Coverage Duration:

12 months.

Other Criteria:

PLAQUE PSORIASIS: Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine, or acitretin. PSORIATIC ARTHRITIS: Failure of one TNF inhibitor (e.g., Humira, Enbrel, Cimzia, Simponi, Simponi Aria, Remicade, Inflectra), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

STIVARGA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

STRENSIQ

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SUBSYS

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Age 18 or greater.

Prescriber Restrictions:

Coverage Duration:

Through the end of the Plan contract year.

Other Criteria:

Patient is already taking and is tolerant to around-the-clock opioid therapy. Patients are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SURMONTIL

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Irritable bowel syndrome.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Depression: Failure of one of the following generic antidepressants, unless contraindicated or clinically significant adverse effects are experienced: bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine succinate, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine, or venlafaxine XR.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SYMDEKO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Presence of homozygous F508del mutation or at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor.

Age Restrictions:

Age greater than or equal to 6 years.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SYMLINPEN

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Previous use of mealtime insulin therapy or an insulin pump.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

SYMPAZAN

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Medical justification supports inability to use clobazam tablets and oral suspension (e.g., contraindications to excipients).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TAGRISSO

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

NON-SMALL CELL LUNG CANCER: Disease is positive for either of the following (a or b): a) sensitizing EGFR mutation (e.g., exon 19 deletion or insertion, exon 21 point mutation (L858R, L861Q), exon 18 point mutation (G719X), exon 20 point mutation (S768I)), OR b) T790M mutation.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TAKHZYRO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Age greater than or equal to 12 years.

Prescriber Restrictions:

Prescribed by or in consultation with an immunologist, allergist, hematologist, or rheumatologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TALZENNA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Confirmation of human epidermal growth factor receptor 2 (HER2)-negative disease and mutation in the BRCA genes.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TARCEVA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

NON-SMALL CELL LUNG CANCER: Disease is positive for a sensitizing EGFR mutation (e.g., exon 19 deletion or insertion, exon 21 point mutation (L858R, L861Q), exon 18 point mutation (G719X), exon 20 point mutation (S768I)). RENAL CELL CARCINOMA: Confirmation of non-clear cell histology.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

PANCREATIC CANCER: Prescribed in combination with gemcitabine.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TASIGNA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Confirmation that the member has Philadelphia chromosome positive disease.

Age Restrictions:

Prescriber Restrictions:

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Prescribed by or in consultation with an oncologist or hematologist. GASTROINTESTINAL STROMAL TUMOR: Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

GASTROINTESTINAL STROMAL TUMOR: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: imatinib, Sutent or Stivarga.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TAVALISSE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of a corticosteroid (e.g., prednisone, methylprednisolone, or dexamethasone), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TECENTRIQ

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

EXTENSIVE-STAGE SMALL CELL LUNG CANCER: Prescribed in combination with carboplatin and etoposide. TRIPLE NEGATIVE BREAST CANCER: Hormone-receptor (HR)-negative, estrogen-receptor (ER)-negative, and human epidermal growth factor receptor 2 (HER2)-negative disease. Prescribed in combination with protein-bound paclitaxel (nab-paclitaxel). Tumor expresses PD-L1.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

NON-SMALL CELL LUNG CANCER: If a known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberration exists, then for ALK+ disease: prior trial of Xalkori, Alecensa, or Zykadia OR for EGFR+ disease: prior trial of Tarceva, Gilotrif, or Iressa.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TECFIDERA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TEGSEDI

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Confirmation of transthyretin (TTR) mutation. Confirmation of amyloid deposition on biopsy or medical justification is provided as to why treatment should be initiated in the presence of a negative biopsy or no biopsy. Member has not had a liver transplant. CONTINUATION OF THERAPY: Maintained on therapy with positive response, including but not limited to improvement in any of the following parameters: 1) neuropathy (motor function, sensation, reflexes, walking ability), 2) nutrition (body mass index), 3) cardiac parameters (Holter monitoring, echocardiography, electrocardiogram, plasma BNP or NT-proBNP, serum troponin), 4) renal parameters (creatinine clearance, urine albumin), 5) ophthalmic parameters (eye exam).

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TENEX

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amlodipine/benazepril, benazepril, benazepril/hydrochlorothiazide, captopril, captopril/hydrochlorothiazide, fosinopril, fosinopril/hydrochlorothiazide, lisinopril, lisinopril/hydrochlorothiazide, quinapril, quinapril/hydrochlorothiazide, losartan, losartan/hydrochlorothiazide, valsartan, valsartan/hydrochlorothiazide, irbesartan, irbesartan/hydrochlorothiazide, candesartan, candesartan/hydrochlorothiazide, carvedilol, labetalol, acebutolol, atenolol, bisoprolol, bisoprolol/hydrochlorothiazide, timolol, nadolol, propranolol, metoprolol, metoprolol/hydrochlorothiazide, pindolol, nifedipine SR, amlodipine, nicardipine.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TETRABENAZINE

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a neurologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TIBSOVO

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Presence of an isocitrate dehydrogenase-1 (IDH1) mutation.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

For age less than 60 years, disease has relapsed or is refractory following treatment with a first-line chemotherapy regimen (e.g., cytarabine, idarubicin, daunorubicin, cladribine, midostaurin).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TREMFYA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a rheumatologist or dermatologist.

Coverage Duration:

12 months.

Other Criteria:

Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine, or acitretin.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TRIHEXYPHENIDYL

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Parkinsons disease/Parkinsonism: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amantadine, levodopa/carbidopa, entacapone, pramipexole, ropinirole, selegiline.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TYMLOS

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Total duration of therapy on parathyroid hormone (PTH) analogs (e.g., Tymlos, Forteo) has not exceeded 2 years.

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of a bisphosphonate (e.g., alendronate) unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

TYSABRI

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

MULTIPLE SCLEROSIS: Prescribed by or in consultation with a neurologist. CROHN'S DISEASE: Prescribed by or in consultation with a gastroenterologist.

Coverage Duration:

12 months.

Other Criteria:

RELAPSING FORMS OF MULTIPLE SCLEROSIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Aubagio, Tecfidera, Gilenya, Avonex, Betaseron, Plegridy, glatiramer, Copaxone, Glatopa, Extavia or Rebif. CROHN'S DISEASE: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Humira or Remicade.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

UPTRAVI

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VALCHLOR

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of one of the following skin-directed therapies unless contraindicated or clinically significant adverse effects are experienced: topical corticosteroid (e.g., betamethasone, clobetasol), topical retinoid (e.g., Targretin, Avage, Fabior, Tazorac), topical imiquimod (Aldara).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VANCOGIN

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

C. Diff diarrhea: 14 days. Staph enterocolitis: 10 days. Recurrent C. Diff: 12 weeks.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VENCLEXTA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

AML: Age 60 years or greater, OR medical justification supports inability to use intensive induction chemotherapy. Prescribed in combination with azacitidine, decitabine, or low-dose cytarabine.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

MANTLE CELL LYMPHOMA: Failure of at least one previous therapy (e.g., a Rituxan based regimen), unless contraindicated or clinically significant adverse effects are experienced. CLL/SLL: Request meets one of the following (a or b): a) Prescribed in combination with Gazyva as first-line therapy OR b) Failure of at least one previous therapy (e.g., Imbruvica, Campath, or high-dose methylprednisolone with Rituxan), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VERSACLOZ

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Psychotic disorder associated with Parkinson's disease.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of clozapine (Clozaril) or FazaClo, unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VERZENIO

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed as a single agent or in combination with an aromatase inhibitor (e.g., letrozole, anastrozole or exemestane) or fulvestrant. For men receiving an aromatase inhibitor: Prescribed in combination with an agent that suppresses testicular steroidogenesis (e.g., gonadotropin-releasing hormone agonists).

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VINBLASTINE

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Confirmation that vinblastine is being used as palliative therapy.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VINCRIStINE

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Patients with the demyelinating form of Charcot-Marie-Tooth syndrome.

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VITRAKVI

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Known acquired tropomyosin receptor kinase resistance mutation.

Required Medical Information:

Confirmation of positive neurotrophic receptor tyrosine kinase gene fusion mutation. Disease is metastatic or surgical resection is likely to result in severe morbidity.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Disease has progressed following standard first-line treatment unless contraindicated, clinically significant adverse effects are experienced, or there are not such alternative treatments available.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VIZIMPRO

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Confirmation of EGFR exon 19 deletion or exon 21 (L858R) substitution mutations.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VOSEVI

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

If cirrhosis is present, confirmation of Child-Pugh A status. Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSAs available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

Coverage Duration:

12 weeks.

Other Criteria:

Criteria will be applied consistent with current AASLD-IDSAs guidance.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VOTRIENT

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

VRAYLAR

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of TWO of the following atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: aripiprazole, ziprasidone, quetiapine, olanzapine, risperidone.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

XALKORI

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

NON-SMALL CELL LUNG CANCER: Disease is ALK, ROS1, or MET positive. INFLAMMATORY MYOFIBROBLASTIC TUMOR, ANAPLASTIC LARGE CELL LYMPHOMA: Disease is ALK-positive.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

XATMEP

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Less than 18 years of age.

Prescriber Restrictions:

ACUTE LYMPHOCYTIC LEUKEMIA: Prescribed by or in consultation with an oncologist or hematologist.
POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist.

Coverage Duration:

12 months.

Other Criteria:

Medical justification as to why member cannot use methotrexate tablets.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

XELJANZ

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

RHEUMATOID ARTHRITIS: Prescribed by or in consultation with a rheumatologist. PSORIATIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist or dermatologist. ULCERATIVE COLITIS (IMMEDIATE-RELEASE ONLY): Prescribed by or in consultation with a gastroenterologist.

Coverage Duration:

12 months.

Other Criteria:

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin. PSORIATIC ARTHRITIS: Failure of one TNF inhibitor (e.g., Humira, Enbrel, Cimzia, Simponi, Simponi Aria, Remicade, Inflectra), unless predominantly axial disease, contraindicated, or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

XEOMIN

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

XERMELO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Prescribed in combination with a somatostatin analog (e.g., octreotide, lanreotide) unless contraindicated or clinically significant adverse effects are experienced.

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Failure of a somatostatin analog (e.g., octreotide, lanreotide) unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

XOLAIR

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

ASTHMA: Positive skin test or in vitro reactivity to a perennial aeroallergen AND immunoglobulin E (IgE) level greater than or equal to 30 IU/mL.

Age Restrictions:

ASTHMA: 6 years of age or older. CHRONIC IDIOPATHIC URTICARIA: 12 years of age or older.

Prescriber Restrictions:

ASTHMA: Prescribed by or in consultation with a pulmonologist, immunologist, or allergist. CHRONIC IDIOPATHIC URTICARIA: Prescribed by or in consultation with an allergist, dermatologist, or immunologist.

Coverage Duration:

12 months.

Other Criteria:

ASTHMA: Failure of one inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced.
CHRONIC IDIOPATHIC URTICARIA: Failure of one H1 Antihistamine (e.g., levocetirizine or desloratadine), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

XOSPATA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Confirmation of the presence of a FLT3 mutation.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

XPOVIO

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Member has received at least 4 prior lines of therapy that include all of the following (a, b, and c): a) Two proteasome inhibitors (e.g., bortezomib, Kyprolis, Ninlaro), b) Two immunomodulatory agents (e.g., Revlimid, pomalidomide, Thalomid), c) One anti-CD38 monoclonal antibody (e.g., Darzalex).

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or hematologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

XTANDI

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Non-metastatic prostate cancer: Concurrent use of a gonadotropin-releasing hormone (GnRH) analog or past bilateral orchiectomy.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or urologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

YERVOY

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

SMALL CELL LUNG CANCER, MALIGNANT PLEURAL MESOTHELIOMA: Failure of a platinum-containing regimen (e.g., cisplatin, carboplatin), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

YONSA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or urologist.

Coverage Duration:

12 months.

Other Criteria:

Medical justification supports inability to use Zytiga. Prescribed in combination with methylprednisolone. Member has previously had bilateral orchiectomy, failed androgen deprivation therapy (ADT) or will use ADT concurrently with Yonsa.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ZALTRAP

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed in combination with irinotecan or FOLFIRI (5-fluorouracil, leucovorin, and irinotecan). Previous treatment with one of the following: oxaliplatin-containing regimen (e.g., FOLFIRI, FOLFOX [leucovorin, 5-fluorouracil, oxaliplatin], CapeOX [capecitabine, oxaliplatin]) OR 5-fluorouracil and leucovorin containing regimen OR capecitabine containing regimen.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ZARXIO

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Myelodysplastic syndrome. Neutropenia in patients with HIV/AIDS. Hematopoietic syndrome of acute radiation syndrome.

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ZEJULA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Completed two or more platinum-based chemotherapy regimens and is in a complete or partial response.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ZELBORAF

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

MELANOMA, ERDHEIM-CHESTER DISEASE: Positive for the BRAF V600 mutation. NON-SMALL CELL LUNG CANCER, COLORECTAL CANCER: Positive for the BRAF V600E mutation. DIFFERENTIATED THYROID CARCINOMA: Positive for the BRAF mutation.

Age Restrictions:

Prescriber Restrictions:

ERDHEIM-CHESTER DISEASE, HAIRY CELL LEUKEMIA: Prescribed by or in consultation with an oncologist or hematologist. ALL OTHER ONCOLOGY INDICATION: Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

NON-SMALL CELL LUNG CANCER: Failure of Tafenlar or Mekinist, unless contraindicated or clinically significant adverse effects are experienced. COLORECTAL CANCER: Failure of irinotecan or platinum-based therapy (e.g., oxaliplatin), unless contraindicated or clinically significant adverse effects are experienced.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ZEPATIER

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

If cirrhosis is present, confirmation of Child-Pugh A status. For genotype 1a, confirmation of presence or absence of NS5A resistance-associated polymorphisms. Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSA available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

Coverage Duration:

12 to 16 wks based on genotype,presence of NS5A resistance-associated polymorphisms,prior treatment.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ZINPLAVA

Prior Authorization Indication:

All FDA-approved indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Confirmation of positive Clostridium difficile test.

Age Restrictions:

Prescriber Restrictions:

Coverage Duration:

4 weeks.

Other Criteria:

Will receive or is currently receiving antibacterial drug treatment for Clostridium difficile infection (e.g., metronidazole, vancomycin, fidaxomicin) concomitantly with Zinplava. Has received appropriate treatment for past CDI recurrences, including a pulsed vancomycin regimen.

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ZYDELIG

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with a hematologist or oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ZYKADIA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

NON-SMALL CELL LUNG CANCER: Disease is ALK or ROS1 positive. If disease is ROS1 positive, Zykadia is prescribed as first-line therapy. INFLAMMATORY MYOFIBROBLASTIC TUMOR: Disease is ALK-positive.

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist.

Coverage Duration:

12 months.

Other Criteria:

Prior Authorization Protocol

Medicare Part D – 2020

Prior Authorization Group Description:

ZYTIGA

Prior Authorization Indication:

All medically accepted indications not otherwise excluded from Part D.

Off Label Uses:

Exclusion Criteria:

Required Medical Information:

Age Restrictions:

Prescriber Restrictions:

Prescribed by or in consultation with an oncologist or urologist.

Coverage Duration:

12 months.

Other Criteria:

Prescribed in combination with prednisone. Member has previously had bilateral orchiectomy, failed androgen deprivation therapy (ADT) or will use ADT concurrently with Zytiga.

ACTEMRA SC	1	CYCLOBENZAPRINE HCL	48
ACTIQ	2	CYTARABINE	49
ACYCLOVIR	3	DAKLINZA	50
ADCIRCA	4	DAURISMO	51
ADEMPAS	5	DICLOFENAC GEL	52
AFINITOR	6	DIPYRIDAMOLE	53
AIMOVIG	7	DISOPYRAMIDE	54
AJOVY	8	DOPTELET	55
ALECENSA	9	DOXEPIN	56
ALUNBRIG	10	DOXEPIN CREAM	57
AMITRIPTYLINE	11	ELIDEL	58
AMITRIPTYLINE/CHLORDIAZEPOXIDE	12	EMEND 40 MG	59
AMITRIPTYLINE/PERPHENAZINE	13	EMFLAZA	60
AMPHOTERICIN B	14	EMGALITY	61
AMPYRA	15	ENBREL	62
ANTI-HISTAMINES	16	ENDARI	63
ANTI-HISTAMINE COMBINATIONS	17	ENTYVIO	64
ARANESP	18	EPCLUSA	65
AUBAGIO	19	EPIDIOLEX	66
BALVERSA	20	EPOETIN	67
BAXDELA	21	ERGOLOID MESYLATES	68
BELEODAQ	22	ERLEADA	69
BELSOMRA	23	ESBRIET	70
BENLYSTA	24	ESTROGENS(Premphase , Premarin , Lopreeza , Mimvey Lo , Femhrt , Activella , Estrace , estropipate, Amabelz , Prempro , Mimvey , Climara , Divigel)	71
BENZTROPINE	25	EXONDYS 51	72
BLEOMYCIN	26	FARYDAK	73
BOSULIF	27	FASENRA	74
BOTOX	28	FERRIPROX	75
BRAFTOVI	29	FIORINAL WITH CODEINE	76
BRIVIACT	30	FIRAZYR	77
BUTABARBITAL	31	FIRDAPSE	78
C1 ESTERASE INHIBITOR	32	FLECTOR	79
CABOMETYX	33	FLUOROURACIL	80
CALQUENCE	34	FORTEO	81
CAPRELSA	35	GALAFOLD	82
CAYSTON	36	GANCICLOVIR	83
CERDELGA	37	GATTEX	84
CEREZYME	38	GILENYA	85
CHLORZOXAZONE	39	GILOTRIF	86
CHORIONIC GONADOTROPIN	40	GLATIRAMER	87
CINQAIR	41	GLIMEPIRIDE	88
CLADRIBINE	42	GLYBURIDE	89
CLOMIPRAMINE	43	GLYBURIDE/METFORMIN	90
COMETRIQ	44	GRANIX	91
COPIKTRA	45	HARVONI	92
COTELLIC	46		
CRYSVITA	47		

HERCEPTIN.....	93	MEKINIST.....	140
HETLIOZ.....	94	MEKTOVI.....	141
HUMAN GROWTH HORMONE.....	95	METAXALONE.....	142
HUMIRA.....	96	METHAMPHETAMINE.....	143
HYDROCODONE.....	97	METHOCARBAMOL.....	144
HYDROXYZINE HCL INJECTION.....	98	METHOTREXATE INJ.....	145
HYDROXYZINE HCL ORAL.....	99	MIRVASO.....	146
HYDROXYZINE PAMOATE.....	100	MOZOBIL.....	147
ICLUSIG.....	101	MULPLETA.....	148
IDHIFA.....	102	NAMENDA.....	149
ILARIS.....	103	NATPARA.....	150
ILUMYA.....	104	NERLYNX.....	151
IMATINIB.....	105	NEULASTA.....	152
IMBRUVICA.....	106	NEUPOGEN.....	153
IMIPRAMINE.....	107	NINLARO.....	154
INDOMETHACIN.....	108	NORTHERA.....	155
INFLECTRA.....	109	NUBEQA.....	156
INGREZZA.....	110	NUCALA.....	157
INLYTA.....	111	NUEDEXTA.....	158
INTERFERON BETA-1A.....	112	NUPLAZID.....	159
INTERFERON BETA-1B.....	113	NUZYRA.....	160
INTUNIV.....	114	OCALIVA.....	161
JAKAFI.....	115	OCREVUS.....	162
JUXTAPID.....	116	ODOMZO.....	163
JYNARQUE.....	117	OFEV.....	164
KADCYLA.....	118	OLUMIANT.....	165
KALYDECO.....	119	OPSUMIT.....	166
KETOROLAC TROMETHAMINE.....	120	ORENITRAM.....	167
KEVZARA.....	121	ORILISSA.....	168
KISQALI(Kisqali , Kisqali Femara Co-Pack).....	122	ORKAMBI.....	169
KORLYM.....	123	OXERVATE.....	170
KUVAN.....	124	PALYNZIQ.....	171
KYNAMRO.....	125	PENNSAID.....	172
LATUDA.....	126	PERSERIS.....	173
LAZANDA.....	127	PHENOBARBITAL.....	174
LEMTRADA.....	128	PIQRAY.....	175
LENVIMA.....	129	PRALUENT.....	176
LEUKINE.....	130	PREVYMIS.....	177
LIDODERM.....	131	PROLASTIN C.....	178
LONSURF.....	132	PROLIA.....	179
LORBRENA.....	133	PROMACTA.....	180
LOTRONEX.....	134	PROTOPIC.....	181
LUCEMYRA.....	135	PROVIGIL.....	182
LYNPARZA TABLET.....	136	PURIXAN.....	183
MAVYRET.....	137	QUALAQUIN.....	184
MEGACE.....	138	RADICAVA.....	185
MEGACE ES.....	139	RAYALDEE.....	186

REMICADE	187	VERZENIO	234
REPATHA	188	VINBLASTINE	235
REVATIO	189	VINCRISTINE	236
REVCovi	190	VITRAKVI	237
REVLIMID	191	VIZIMPRO	238
REXULTI	192	VOSEVI	239
RUBRACA	193	VOTRIENT	240
RYDAPT	194	VRAYLAR	241
SILIQ	195	XALKORI	242
SIMPONI(auto-injector, prefilled syringe)	196	XATMEP	243
SIMPONI ARIA	197	XELJANZ	244
SOMA	198	XEOMIN	245
SOMAVERT	199	XERMELO	246
SOVALDI	200	XOLAIR	247
SPRAVATO	201	XOSPATA	248
SPRITAM	202	XPOVIO	249
SPRYCEL	203	XTANDI	250
STELARA IV	204	YERVOY	251
STELARA SC	205	YONSA	252
STIVARGA	206	ZALTRAP	253
STRENSIQ	207	ZARXIO	254
SUBSYS	208	ZEJULA	255
SURMONTIL	209	ZELBORAF	256
SYMDEKO	210	ZEPATIER	257
SYMLINPEN	211	ZINPLAVA	258
SYMPAZAN	212	ZYDELIG	259
TAGRISSE	213	ZYKADIA	260
TAKHZYRO	214	ZYTIGA	261
TALZENNA	215		
TARCEVA	216		
TASIGNA	217		
TAVALISSE	218		
TECENTRIQ	219		
TECFIDERA	220		
TEGSEDI	221		
TENEX	222		
TETRABENAZINE	223		
TIBSOVO	224		
TREMFYA	225		
TRIHENYPHENIDYL	226		
TYMLOS	227		
TYSABRI	228		
UPTRAVI	229		
VALCHLOR	230		
VANCOCIN	231		
VENCLEXTA	232		
VERSACLOZ	233		